Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -16.04% | -- | -- | -- | -- |
| Gross Profit | 16.04% | -- | -- | -- | -- |
| SG&A Expenses | -22.74% | 7.43% | -21.87% | 162.99% | -40.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.62% | -4.41% | -23.28% | 60.69% | -17.38% |
| Operating Income | 26.62% | 4.41% | 23.28% | -60.69% | 17.38% |
| Income Before Tax | 30.14% | 1.06% | 75.47% | -469.32% | 58.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.14% | 1.06% | 75.47% | -469.32% | 58.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.14% | 1.06% | 75.47% | -469.32% | 58.44% |
| EBIT | 26.62% | 4.41% | 23.28% | -60.69% | 17.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 43.59% | 25.00% | 82.86% | -366.67% | 66.09% |
| Normalized Basic EPS | 46.15% | 24.00% | 82.22% | -337.50% | 63.89% |
| EPS Diluted | 43.59% | 25.00% | 82.86% | -366.67% | 66.09% |
| Normalized Diluted EPS | 46.15% | 24.00% | 82.22% | -337.50% | 63.89% |
| Average Basic Shares Outstanding | 21.94% | 32.43% | 39.95% | 26.72% | 23.37% |
| Average Diluted Shares Outstanding | 21.94% | 32.43% | 39.95% | 26.72% | 23.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |